Northern Trust’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-139,074
| Closed | -$556K | – | 4488 |
|
|
2025
Q2 | $556K | Sell |
139,074
-289,050
| -68% | -$716K | ﹤0.01% | 3616 |
|
|
2025
Q1 | $390K | Sell |
428,124
-22,640
| -5% | -$31.4K | ﹤0.01% | 3674 |
|
|
2024
Q4 | $1.25M | Buy |
450,764
+11,919
| +3% | +$45.3K | ﹤0.01% | 3288 |
|
|
2024
Q3 | $2.3M | Buy |
438,845
+27,469
| +7% | +$143K | ﹤0.01% | 2922 |
|
|
2024
Q2 | $1.83M | Sell |
411,376
-8,503
| -2% | -$41.2K | ﹤0.01% | 2938 |
|
|
2024
Q1 | $3.22M | Sell |
419,879
-4,828
| -1% | -$26.5K | ﹤0.01% | 2735 |
|
|
2023
Q4 | $1.81M | Buy |
424,707
+90,060
| +27% | +$320K | ﹤0.01% | 3051 |
|
|
2023
Q3 | $1.41M | Buy |
334,647
+34,264
| +11% | +$174K | ﹤0.01% | 3125 |
|
|
2023
Q2 | $1.67M | Buy |
300,383
+254,501
| +555% | +$1.5M | ﹤0.01% | 3109 |
|
|
2023
Q1 | $263K | Sell |
45,882
-61
| -0.1% | -$161 | ﹤0.01% | 3731 |
|
|
2022
Q4 | $48.2K | Buy |
45,943
+5,639
| +14% | +$9.86K | ﹤0.01% | 4294 |
|
|
2022
Q3 | $108K | Sell |
40,304
-6,686
| -14% | -$24.2K | ﹤0.01% | 4088 |
|
|
2022
Q2 | $224K | Sell |
46,990
-66,833
| -59% | -$291K | ﹤0.01% | 3873 |
|
|
2022
Q1 | $466K | Sell |
113,823
-6,939
| -6% | -$40.8K | ﹤0.01% | 3766 |
|
|
2021
Q4 | $823K | Buy |
120,762
+4,661
| +4% | +$40.3K | ﹤0.01% | 3615 |
|
|
2021
Q3 | $1.34M | Sell |
116,101
-4,642
| -4% | -$72.4K | ﹤0.01% | 3445 |
|
|
2021
Q2 | $2.06M | Buy |
120,743
+5,274
| +5% | +$91.8K | ﹤0.01% | 3344 |
|
|
2021
Q1 | $2.29M | Buy |
115,469
+22,663
| +24% | +$500K | ﹤0.01% | 3169 |
|
|
2020
Q4 | $1.92M | Buy |
92,806
+42
| +0% | +$1K | ﹤0.01% | 3219 |
|
|
2020
Q3 | $2.44M | Buy |
+92,764
| New | +$2.3M | ﹤0.01% | 2961 |
|
Northern Trust's INZY Position: Q3 2025 in Review
Northern Trust sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 139,074 shares — an estimated $556K sold.
Northern Trust first reported a position in INZY in Q3 2020 and held it in 20 quarters. The position peaked at $3.22M in Q1 2024. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- Northern Trust reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- Northern Trust sold 139,074 Inozyme Pharma shares in Q3 2025, an estimated $556K.
- Northern Trust first reported a position in Inozyme Pharma in Q3 2020 and held it in 20 quarters.
- Northern Trust's Inozyme Pharma position peaked at $3.22M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on Northern Trust's 13F filing for Q3 2025, filed 14 Nov 2025.